Add BrightSurf on Google Email

University of Pennsylvania School of Medicine


'Chromosomal Chaos:' Complex array of mutations found in rare, aggressive leukemia

Researchers at the University of Pennsylvania School of Medicine identified a previously unknown genomic landscape in Sezary syndrome, a rare and aggressive leukemia. The study reveals recurrent loss-of-function mutations in genes regulating epigenetic pathways, including ARID1A, which occurred in over 40% of the genome studied.

SourceUniversity of Pennsylvania School of Medicine·JournalNature Communications·DateOct 7, 2015

Treatment for heparin-induced blood disorder revealed in structure of antibody complex

A team of researchers from the University of Pennsylvania School of Medicine has elucidated the structure of a protein complex at its root, which may hold therapeutic potential for treating heparin-induced thrombocytopenia (HIT). The study found that an antibody called RTO disrupts this complex, preventing platelet activation and clot ...

SourceUniversity of Pennsylvania School of Medicine·JournalNature Communications·DateOct 6, 2015

International team of researchers co-led by Penn aims to revolutionize understanding of how gene variants affect organ transplant outcomes

A large international team of researchers is investigating the genetic factors behind transplant successes and failures. The project, iGeneTRAiN, has generated genomics data for over 32,000 organ donors and recipients, aiming to discover genetic variants that lead to rejection and other complications.

New enzyme-replacement therapy shows promise for genetic lipid disease treatment

A new enzyme-replacement therapy, Sebelipase Alfa, has been shown to effectively treat Lysosomal Acid Lipase Deficiency by reducing disease-related liver and blood cholesterol abnormalities. The therapy, which targets hepatocytes, resulted in lower cholesterol levels and reduced liver fat content in patients with the condition.

SourceUniversity of Pennsylvania School of Medicine·JournalNew England Journal of Medicine·DateSep 9, 2015

Penn team: Sustained remission of multiple myeloma after personalized cellular therapy

A multiple myeloma patient experienced complete remission after receiving a personalized cellular therapy called CTL019, which targets cancerous white blood cells. The treatment was combined with chemotherapy and an autologous stem cell transplant, and the patient remains in remission over 12 months after infusion.

SourceUniversity of Pennsylvania School of Medicine·JournalNew England Journal of Medicine·DateSep 9, 2015

Penn researchers report long-term remissions in first personalized cell therapy trial

A clinical trial of a personalized cell therapy, CTL019, achieved an overall response rate of 57% and complete remissions in eight out of 14 patients with chronic lymphocytic leukemia (CLL). The therapy, developed by Penn researchers, involves reprogramming patients' own T cells to hunt and kill cancer cells.

SourceUniversity of Pennsylvania School of Medicine·JournalScience Translational Medicine·DateSep 2, 2015

Fears of potentially blinding complication from Avastin eye injections overblown, says Penn study

A new Penn study analyzing insurance claims data suggests that repackaged Avastin injections do not carry a higher risk of endophthalmitis than commercially available Lucentis. This finding contradicts the FDA's planned restriction on Avastin's ophthalmic use and may inadvertently increase infection risk for patients.

SourceUniversity of Pennsylvania School of Medicine·JournalJAMA Ophthalmology·DateAug 13, 2015

Penn study finds link between physician training and brand name prescribing

A new Penn study found that internal medicine residents are twice as likely to prescribe expensive brand-name statins when supervised by senior physicians who also use them. The study's findings represent an opportunity to improve value in healthcare spending and highlight the importance of redesigning graduate medical education.

SourceUniversity of Pennsylvania School of Medicine·JournalJournal of General Internal Medicine·DateJul 23, 2015